Protocol Ledger

NCT06897579 · Phase II · TERMINATED

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small

Interventional Phase II clinical trial protocol NCT06897579 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-07 Enrollment: 40 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06897579
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06897579
Protocol FieldVerified Registry Value
NCT IdentifierNCT06897579
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment40 participants (ACTUAL)
Registered Start Date2025-04-07
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI